United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

1 Mar 2017
Change (% chg)

€0.08 (+0.68%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ABLX.BR


Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)


Beta: 1.63
Market Cap(Mil.): €717.95
Shares Outstanding(Mil.): 61.08
Dividend: --
Yield (%): --


  ABLX.BR Industry Sector
P/E (TTM): -- 44.07 29.88
EPS (TTM): -0.32 -- --
ROI: -8.19 -3.76 13.08
ROE: -17.46 5.68 14.24

BRIEF-Ablynx FY revenue rises 10 pct

* FY net cash burn of EUR 72.2 million, in line with previously guided range of EUR 65-75 million

Feb 23 2017

BRIEF-Ablynx: Results support advancement of vobarilizumab into phase III development

* Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, a potential best-in-class treatment for rheumatoid arthritis

Feb 09 2017

BRIEF-Ablynx submits marketing authorisation for caplacizumab

* Ablynx submits a marketing authorisation application to the European medicines agency for caplacizumab, its anti-vwf nanobody, for the treatment of aTTP

Feb 06 2017

BRIEF-Ablynx's partner Merck reports encouraging results with nanobody

* Ablynx's partner, Merck KGaA, reports encouraging results with the bi-specific nanobody anti-il-17a/f (m1095) in a phase ib clinical study in patients with psoriasis

Jan 26 2017

BRIEF-Van Herk Investments announces 10.07 pct shareholding in Ablynx

* Van Herk Investments B.V. announces 10.07 pct shareholding in Ablynx, an increase from a former position of 5.40 pct (August 2016) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 24 2017

BRIEF-Ablynx has 61,076,074 shares outstanding after warrant exercise

* As a result of this transaction, Ablynx now has 61,076,074 shares outstanding Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 18 2017

BRIEF-Ablynx initiates the phase IIb "respire" study of anti-rsv nanobody

* Ablynx initiates the phase IIB "respire" study of its wholly-owned, first-in-class, inhaled anti-rsv nanobody, ALX-0171, for the treatment of RSV infections in hospitalised infants

Jan 11 2017

BRIEF-Ablynx 9-month net profit turns to 10.9 million euros

* 9-month revenue 68.9 million euros ($73.22 million) versus 53.6 million euros year ago

Nov 23 2016

BRIEF-FMR LLC announces 9.10 pct shareholding in Ablynx

* FMR LLC announces 9.10 pct shareholding in Ablynx Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 18 2016

BRIEF-Ablynx announces warrant exercise

* Additional 938 common shares have been issued by the company in exchange for 5,102.72 euros as the result of the exercise of warrants Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 10 2016

More From Around the Web

Earnings vs. Estimates